Navigation Links
Global Ubiquitin Proteasome Research and Development Market to Surpass $5.5 Billion by 2018: BCC Research
Date:7/23/2013

Wellesley, MA (PRWEB) July 23, 2013

According to a new technical market research report, Ubiquitin Proteasome: Global Markets for Research Tools, Diagnostics and Drug Discovery (Report code: PHM066B) from BCC Research (http://www.bccresearch.com), the global ubiquitin proteasome research and development market was valued at nearly $2.9 billion in 2013. BCC Research expects the market to reach more than $5.5 billion by 2018, and register a five-year compound annual growth rate (CAGR) of 14.2% for the period 2013 to 2018.

Ubiquitin proteasome system (UPS) represents one of the most studied and challenging areas in basic and applicable science. The scientists who discovered this cellular phenomenon were awarded the Nobel Prize in Chemistry in 2004. Since then, ubiquitin ligases and proteasome function have become one of the major targets for pharmaceutical and drug development companies. However, despite the accumulation of basic knowledge about the ubiquitination process and proteasome function, progress in drug screening and therapeutic development has been delayed.

Until 2012, there was only one approved product on the market, Velcade (bortezomib), a proteasome inhibitor, and its success for Millennium Pharmaceuticals (a subsidiary of Takeda) as a major blockbuster pushed the industry towards more rigorous research and development. Velcade is a therapeutic treatment for patients with multiple myeloma, a type of bone marrow cancer that can damage one’s immune system.

According to BCC Research, the global market value of Velcade was more than $2 billion in 2012. The market is expected to reach $2.6 billion by 2013 and $4.5 billion by 2018, registering a CAGR of 11.4% for the period 2013 to 2018.

Today, there is new second-generation proteasome inhibitor on the market: Kyprolis, an immunomodulatory therapy marketed by Onyx Pharmaceuticals. The FDA approved Kyprolis in 2012 to treat patients who suffer from multiple myeloma and have received at least two prior therapies including treatment with Velcade. Many analysts predict that sales of this drug will increase dramatically in the next five years, depending on further applications and regulatory approvals. According to BCC Research, the global market value of Kyprolis was $62 million in 2012. This market is expected to reach $260 million by 2013 and further increase to $1 billion by 2018, to register a CAGR of 30.9% for the period 2013 to 2018.

Recent developments in the field of proteasome inhibitors bring new perspective and alternatives that may change the current market. This report details the current state of drug discovery in this field and new technologies in development and describes potential novel commercial venues in diagnostics and drug development. This study discusses the major players, current and future trends, influences, drivers and challenges for each segment, and includes forecasts for the next five years.

This report is intended for business development professionals, entrepreneurs and other investors who need to fully understand and properly evaluate each segment in the market for ubiquitin proteasome drug discovery, diagnostics, and research tools applications.

Read the full story at http://www.prweb.com/releases/2013/7/prweb10941846.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Global Printed and Flexible Sensors 2013 Report: Forecasts, Players, Opportunities
2. Global Graphite Market 2012-2016
3. Global Activated Carbon Market 2012-2016: Latest Market Share, Growth, Analysis, Size, Trends & Forecast Research Report 2012-2016 Available at Marketresearchreports.biz
4. US Dermatophytic Onychomycosis Market Discussed by GlobalData in Topical Report Now Available at MarketPublishers.com
5. Global GIS Market in the Retail Industry to 2016: Industry Analysis, Growth, Strategy, Size, Shares, Trend and Forecast Research Report Available at MarketResearchReports
6. Growing Awareness & Increasing Number of Indications Drive the Global Intravenous Immunoglobulin Market, According to a New Report by Global Industry Analysts, Inc.
7. TriMix for Travel Now Available at KRS Global Biotechnology
8. Top Five Global Cardiovascular Drug Companies 2013 Report Features Players such as Pfizer and AstraZeneca
9. Stem Cells Market is Expected to Reach USD 119.51 Billion Globally in 2018: Transparency Market Research
10. Global Biometric Systems Market Forecast Report - Opportunities to 2018
11. NineSigma Evolves Global Open Innovation through Social Media Platform, NineSights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... ... May 25, 2016 , ... Lajollacooks4u has become a rising hotspot ... rated one of its top attractions. Fortune 500 companies, such as Illumina, Hewlett-Packard, ... unique and intimate team-building experience. , Each event kicks off with an olive oil ...
(Date:5/25/2016)... ... 2016 , ... Scientists at the University of Athens say they have evidence ... hampering the research that could lead to one good one. Surviving Mesothelioma has just ... , The team evaluated 98 mesothelioma patients who got a second ...
(Date:5/24/2016)... 2016   MedyMatch Technology Ltd ., the data analytics ... decision support tools in the emergency room, announced today that ... Advanced Technology Industries (IATI) BioMed Conference. The ... 15th National Life Sciences and Technology Week, and is being ... in Tel Aviv, Israel . Gene ...
(Date:5/23/2016)... , May 23, 2016 Zimmer Biomet Holdings, ... healthcare, today announced that its Board of Directors has approved ... the second quarter of 2016. The cash ... about July 29, 2016 to stockholders of record as of ... of dividends are subject to approval of the Board of ...
Breaking Biology Technology:
(Date:3/11/2016)... , March 11, 2016 ... new market research report "Image Recognition Market by Technology ... (Marketing and Advertising), by Deployment Type (On-Premises and Cloud), ... To 2022", published by MarketsandMarkets, the global market is ... to USD 29.98 Billion by 2020, at a CAGR ...
(Date:3/10/2016)... 2016   Unisys Corporation (NYSE: UIS ) ... (CBP) is testing its biometric identity solution at the Otay ... to help identify certain non-U.S. citizens leaving the country. ... to help determine the efficiency and accuracy of using biometric ... will run until May 2016. --> the ...
(Date:3/9/2016)... , March 9, 2016 ... identified that more than 23,000 public service employees either ... been receiving their salary unlawfully.    --> ... government identified that more than 23,000 public service employees ... had been receiving their salary unlawfully.    --> ...
Breaking Biology News(10 mins):